Prodetoxon

Prodetoxon is a sustained-release subcutaneous depot implant containing 1000 mg of naltrexone, a competitive opioid receptor antagonist, and 10 mg of triamcinolone, a corticosteroid added to reduce local tissue inflammation. Developed in Russia by Fidelity Capital and NPK ECHO, and approved by the Russian Ministry of Health in 2005, the implant is formulated as a composite cylinder (18 mm long, 8.5 mm in diameter) that slowly dissolves over approximately 2 to 3 months. It provides stable plasma concentrations of naltrexone and its active metabolite 6β-naltrexol, effectively blocking the effects of exogenous opioids. Prodetoxon is indicated for the prevention of relapse to opioid dependence and has been evaluated in clinical trials for co-morbid amphetamine and opioid dependence, as well as for improving HIV treatment outcomes in opioid-dependent individuals.

Brand names

Prodetoxon

Other names

naltrexone implantsustained-release naltrexone implantnaltrexone depot implantProdetoxone